The 340B Revenue Leak You Don’t See: Why Audit Services Are a Margin Strategy
Discover how 340B Audit Services can uncover hidden revenue leaks, strengthen program oversight, and help healthcare organizations protect 340B margins.
340B Audit Services is critical to the protection of program savings for the 340B Drug Pricing Program, which is essential for safety-net providers. Under 340B, hospitals and health centers that serve certain populations can use savings to help meet Medicaid budget needs and provide mission-specific services that are operating at a loss. However, there is a growing risk landscape under the program’s benefits that could be smashing away its savings.
Many organizations believe that their 340B program is running at a peak performance level. They leave compliance to third parties and take any savings reported as genuine. However, things are not as simple as they sound. Revenue leakage has become commonplace in 340B programs and frequently goes undetected by internal teams, and now is under scrutiny by regulators and auditors alike. This article focuses on the hidden leakage of revenue in 340B programs and why 340B Audit Services have grown to be more than just a compliance requirement.
The 2026 340B Audit Landscape and Key Changes
Audit readiness in past years tended to be more point-in-time compliance. In 2026, HRSA has been transformed in many ways. The Office of the Bureau of Primary Health Care (BPC) has reorganized its regions to conduct more frequent Operational Site Visits (OSVs), as well as incorporate 340B‐based metrics into health center performance reviews. Manufacturer compliance has reached a fever pitch. With the 45-day window for 340B ESP data submissions becoming a standard industry gatekeeper, entities that fail to maintain precise, automated data flows face immediate pricing denials.
A single finding during a HRSA audit can lead to repayment of discounts to manufacturers, program suspension, or termination from the program entirely. HRSA continues to release initial audit reports with repayment findings, including diversion findings. Organizations that fail to prepare for these audits face significant financial exposure. For CFOs, 340B Audit Services provide a structured way to assess financial and compliance exposure before those findings become costly problems.
The Hidden Revenue Leak: Where 340B Savings Disappear
Revenue leakage in 340B programs occurs in multiple ways. Some are operational. Others are structural. Many remain invisible to internal teams without specialized audit capabilities.
Leak 1: Contract Pharmacy Misalignment
When multiple locations are part of an organization, they may find that eligibility configurations vary from one contract pharmacy to another that is administered by the same organization. Other pharmacies have strict policies that prevent you from saving what you are supposed to save. Others use more liberal controls and put the organization at risk of compliance.
Revenue can be recovered from a single claim-by-claim audit of every pharmacy, looking at both captured and uncaptured claims, which generally shows there are a lot of missed savings opportunities. The consistent configuration across all locations can create more legitimate savings and minimize compliance risk. Strong 340B Audit Services should therefore examine contract pharmacy performance at the transaction level. Reviewing only aggregate savings figures leaves important gaps.
Leak 2: Third-Party Administrator Revenue Diversion
The recent CVS Health litigation has exposed a systemic risk in 340B administration. Several academic and nonprofit health systems filed lawsuits alleging that CVS Health and its subsidiaries improperly pocketed approximately $250 million of 340B savings from 2020 to 2025. According to the complaints, the third-party administrator would discreetly flag claims eligible for a 340B discount after the point of sale. The PBM would then negotiate an artificially lower rate between its subsidiaries while retaining the difference between the amount paid by outside insurers and the reduced reimbursement amount.
This should be of interest to the entire industry. Contract analytics, independent auditing and the ability to closely monitor the Pharmacy Revenue Cycle will be among the areas of increased resources that CFOs must invest in as payer-provider relationships are growing more complex. Traditionally, revenue integrity programs have centered on claims and denials management. They could now extend further into 340B administration, PBM contracts, and specialty-pharmacy programs. When third-party administrators handle these programs and their data, independent 340B audit services give organizations added oversight. This review helps verify program accuracy, compliance, and financial controls.
Leak 3: Provider Eligibility Gaps
Validating eligible providers is a key component of demonstrating compliance during a HRSA audit. Failure to demonstrate provider eligibility for a tested transaction can result in diversion findings, which may warrant a corrective action plan and possible manufacturer repayment.
During an audit, HRSA requests a list of the covered entity’s eligible providers, including names, NPI values, affiliation status, and start and termination dates. For each transaction tested, the entity must provide documentation validating provider affiliation. Because HRSA audits often test 60 or more transaction samples, advanced organization of these records is essential. 340B Audit Services help identify missing documentation before an external review exposes the gap.
Leak 4: Documentation and Record-Keeping Failures
A compliant program is built on comprehensive policies and procedures that match actual daily workflows. In 2026, HRSA auditors are specifically looking for the “12 Required Elements” of 340B compliance, but they are also testing the application of these rules.
Key compliance components include:
- Patient definition oversight: Ensure every script billed to 340B originated from a documented encounter with a qualified provider at a registered site.
- Duplicate discount prevention: Especially critical for Medicaid patients. Your entity must have a clear mechanism to prevent both a 340B discount and a Medicaid rebate on the same unit of drug.
- OPAIS record accuracy: Your OPAIS record must be updated in real time. Any discrepancy in site addresses or pharmacy associations is a high-probability audit finding.
A focused 340B Audit Services engagement reviews whether written policies match actual operational practices. This distinction matters because documented policies alone do not prove compliant execution.
The True Cost of Compliance Failures
The financial consequences of 340B non-compliance are severe. Entities that fail audits face several risks. Repayment of discounts to manufacturers. HRSA audits can result in findings requiring covered entities to repay 340B discounts to manufacturers. These repayments can reach millions of dollars for large health systems. Program suspension or termination. A single finding during a HRSA audit can lead to repayment of discounts, program suspension, or termination from the program entirely. For organizations relying on 340B savings to subsidize behavioral health programs, oncology services, rural outreach, and care for uninsured populations, this is catastrophic.
Public exposure of findings. Once an audit report is finalized, findings and corrective actions are summarized on HRSA’s public website. Manufacturers receive a public notice identifying program violations and requiring repayment. This public disclosure creates reputational risk beyond the financial penalties. This is where 340B Audit Services shift from a compliance expense to a financial control. Early detection gives leadership more time to correct errors and protect program revenue.
Why Audit Services Are a Margin Strategy
Given the growing regulatory complexity and financial exposure, 340B Audit Services have become a margin strategy, not merely a compliance expense. Here is why.
Reason 1: Preventive vs. Corrective Compliance
Many organizations think that their program is being managed effectively, and only call in the experts when it is required by an audit or manufacturer restrictions. If the rules change, reactions are likely to be remedial and not strategic and deliberate, making programs and patients vulnerable. It’s a big risk to depend exclusively on your third party. TPAs are not compliance officers but software providers. Organizations must ensure they have audit capabilities that are independent to detect any undetected compliance risk and precisely determine where reported savings are defensible to be audit-ready. The best 340B Audit Services programs are those that uncover issues before they are discovered by regulators or manufacturers.
Reason 2: Protecting Hundreds of Millions in Savings
The money risk is very high. In the lawsuits filed against CVS Health, it is claimed that $250 million was diverted from only three health systems since 2011. Just one of the University of Michigan-related lawsuits claims over $66 million in lost revenues. Any disruption in 340B revenue has negative financial impact, particularly for hospitals that are already facing a national issue with Medicaid reimbursements that frequently do not meet the cost of care. The loss of those dollars converts into operating-budget pressure in no time. Effective 340B Audit Services help the leadership determine if program savings are being realized to benefit the organization.
Reason 3: Independent, Objective Oversight
The mission is to be vendor-agnostic to make a difference. Audit firms that are not involved in a sales, claims management or pharmacy function may act as an impartial compliance advocate. Clients will have a realistic understanding of where the savings are real, where risks may be masked, and where choices are in line with long-term program integrity. Strong 340B programs are not designed to maximize the margin. They are based on trust, documentation and accountability. This is the foundation of all engagements. The model of governance can be reinforced through Independent 340B Audit Services, which help to clearly distinguish program oversight from day-to-day administration.
Reason 4: Real-Time Compliance Monitoring
The future of the 340B program will favor organizations that operate transparently and maintain governance structures capable of withstanding scrutiny over time.
340B Audit Services provide:
- Ongoing readiness: Creating an ongoing compliance plan to ensure ongoing preparedness for HRSA audits.
- Quarterly risk targeted audits: Audits are conducted quarterly for high volume sites, contract pharmacies and work flows that would have the greatest compliance or financial impact.
- Real-time compliance monitoring: Monitoring updates to regulations and manufacturer policy in real-time.
The 2026 Executive 340B Audit Services Framework
An audit readiness program is the key to the difference in survival between a 340B program that passes regulatory scrutiny and one that is considered for repayment. Audits that are not a part of a continuous discipline will be more susceptible to diversion findings, manufacturer clawbacks, and program suspension. There must be three different levels of oversight to establish a defensible framework. Each layer is used for a specific function. Understandably, they work together to provide a full governance framework that safeguards your program against undetected revenue leakage and regulatory risk.
Layer 1: Continuous Internal Monitoring
Internal monitoring is the first line of defense. It’s not an audit preparation. It’s about running a program that is compliant on a daily basis. No organization can afford to wait until an audit has been announced to check its claims.
Internal Monitoring Activities and Frequency
| Monitoring Activity | Frequency | Purpose |
|---|---|---|
| Claim-to-encounter verification | Daily/Weekly | Confirm every 340B claim matches an EHR encounter |
| Sample claim audits | Monthly | Create documented trail of oversight for auditors |
| OPAIS record reconciliation | Quarterly | Ensure site addresses and pharmacy associations are current |
| Medicaid billing form review | Monthly | Verify compliance with state-specific requirements |
| Provider eligibility verification | Monthly | Confirm provider affiliation and NPI accuracy |
The ones who are good at internal monitoring consider monitoring as a discipline, not a task. They provide clear accountability, record all reviews and escalate any findings promptly. This discipline changes the way that internal monitoring is done, turning it from a hindrance to a benefit. This also lays a groundwork for better 340B Audit Services as the internal reviewers get organized and traceable records.
Layer 2: Independent External Audits
Internal monitoring catches operational errors. External audits catch structural problems. They are not redundant. They are complementary. HRSA recommends that covered entities engage an independent third party for annual audits. The reason is straightforward. Internal teams often cannot see their own blind spots. They know the workflows, trust the systems, and assume the data is correct. An external set of eyes brings objectivity and specialized expertise. 340B Audit Services provide this independent review while giving executives a clearer view of financial and compliance risk.
| Audit Component | What Is Reviewed | Why It Matters |
|---|---|---|
| Contract pharmacy configurations | Accumulator logic, eligibility rules, platform settings | Inconsistencies create missed savings or compliance risk |
| Provider eligibility documentation | Employment agreements, credentialing, termination dates | Missing documentation leads to diversion findings |
| Purchasing and inventory | Drug acquisition patterns, inventory reconciliation | Discrepancies suggest diversion or duplicate discounts |
| Payer and policy applicability | State-specific Medicaid rules, carve-in/carve-out decisions | Misapplication creates repayment exposure |
The external audit is not a pass/fail test. It is a diagnostic tool. The goal is to identify where your program is exposed and build a remediation plan before regulators find the same issues.
Layer 3: Manufacturer Data Validation
The 340B program is based on a data exchange between covered entities and drug manufacturers. A mistake in that transaction can result in price denials, delayed access to discounts or repayment requirements. Manufacturers have been accepting 340B ESP data submissions since 2023. Inaccurate data will result in pricing denials for covered entities. 45 days of submission has become a standard industry gatekeeper. Specialized 340B Audit Services should validate submission workflows and supporting records before data reaches the manufacturer.
| Validation Component | What Is Verified | Risk of Failure |
|---|---|---|
| ESP submission accuracy | NPI, site address, drug code, payer matching | Pricing denials, restricted access |
| Submission timeliness | 45-day submission window | Delayed discounts, cash flow disruption |
| Payer-specific alignment | Payer requirements for each drug code | Rejections, administrative burden |
Why This Framework Works
Each layer of the three layer structure has a different purpose and that is why it works. There is a system of internal monitoring to ensure compliance on a day-to-day basis. Structural risks are identified through external audits. Data validation provides access for manufacturers. They form a holistic 340B revenue leakage solution that addresses three biggest threats to 340B revenue: operational mistakes, structural flaws, and data failures.
The Three-Layer Audit Framework
| Layer | Primary Purpose | Frequency | Ownership |
|---|---|---|---|
| Internal Monitoring | Catch operational errors before claims leave | Daily/Monthly | Internal team |
| External Audits | Identify structural risks and blind spots | Annually | Independent third party |
| Data Validation | Ensure manufacturer pricing access | Per submission cycle | Dedicated specialist |
Organizations that implement all three layers consistently improve financial visibility. They catch errors before they become findings. They identify missed savings before they become permanent losses. They enter regulatory audits with stronger documentation. For CFOs, 340B Audit Services connect compliance controls with measurable financial outcomes. This makes audit activity part of revenue protection rather than a separate administrative function.
How Billing Care Solutions Supports 340B Compliance
Billing Care Solutions provides specialized 340B Audit Services designed to identify hidden revenue leakage and strengthen compliance. The team understands the 2026 regulatory landscape, including HRSA’s evolving audit priorities, manufacturer data requirements, and contract pharmacy governance standards.
Our 340B Audit Services include:
Practice Health Audit: We evaluate the performance of your current 340B program and compare it to industry best practices. Documentation gaps, eligibility errors and contract pharmacy misalignments are identified. We calculate the cost of savings that are passed over and compliance risks.
Contract Pharmacy Audit: We review each contract pharmacy relationship independently, analyzing configurations, accumulator logic, and platform settings. We identify where savings are being missed and where compliance risk exists.
Provider Eligibility Audit: We verify that every provider associated with 340B claims is properly documented and eligible. We prepare provider lists, employment agreements, and credentialing documentation for audit readiness.
OPAIS Record Review: We audit your OPAIS record for accuracy, ensuring all site addresses and pharmacy associations are current and match your contract pharmacy agreements.
Manufacturer Data Audit: We review your 340B ESP submissions to ensure data accuracy and prevent pricing denials.
Documentation Preparation: We help you develop comprehensive policies and procedures that match your actual workflows, ensuring you have the “12 Required Elements” documented and organized.
Giving measurable financial outcomes is our approach. We measure saved dollars, uncover non-compliance issues and create long-term sustainable compliance programs to safeguard your 340B program. Call Billing Care Solutions today, and speak with someone about the 340B Audit Services that can help you maintain your margins and support your program.
Conclusion
The 340B Drug Pricing Program is a key source of financial support for safety-net providers. However, there is a risk of hidden revenue leakage which could erode those savings. These misalignments in contracts, unclear TPA reimbursement structures, provider gaps, and documentation errors are going to lead to financial risk. The regulatory landscape has shifted toward higher scrutiny and stronger documentation expectations. A single finding during a HRSA audit can lead to repayment of discounts, program suspension, or termination. The lawsuits against CVS Health reveal how dependent many health systems have become on 340B revenue and how vulnerable they are to diversion.
340B Audit Services are not just a compliance cost, but a margin strategy. Independent, objective monitoring can uncover hidden revenue loss, avoid expensive findings, and foster ongoing governance systems. Those that rely solely on TPAs and reactive compliance face growing financial risk. The question is not whether you can afford 340B Audit Services. It is whether you can afford to ignore the revenue leakage you do not see. Contact Billing Care Solutions today and discover how 340B Audit Services can help you protect your margins and strengthen your program.
